NanoVation-GS

Their core work

NanoVation-GS is an Israeli SME that develops nanotechnology-based sensor devices for medical diagnostics and respiratory monitoring. Their core technology applies microfluidic and nanosensor platforms to detect diseases from exhaled breath — initially targeting gastric cancer screening, then pivoting to chronic respiratory disease monitoring (COPD). They design compact, patient-facing monitoring hardware intended for home use, bridging the gap between laboratory-grade sensing and consumer health devices.

What they specialise in

How they've shifted over time

NanoVation-GS began as a consortium partner on SNIFFPHONE (2015–2019), contributing nanosensor expertise to a broader smartphone-based breath screening platform targeting gastric cancer. From 2019 onward, they shifted to leading their own projects under the SenseGuard brand, narrowing focus from general disease screening to a specific, market-ready respiratory monitoring device for COPD patients at home. This trajectory shows a classic SME maturation: from technology contributor in someone else's vision to product owner driving commercialization of their own device.

NanoVation-GS is moving from research-stage sensor technology toward a specific commercial product (SenseGuard) for chronic respiratory home care — expect them to seek clinical validation partners and distribution channels next.

How they like to work

NanoVation-GS transitioned from participant to coordinator across their H2020 history, indicating growing independence and project leadership capability. With 10 consortium partners across 6 countries from just 3 projects, they engage in moderately sized international consortia rather than massive ones. Their SME Instrument trajectory (Phase 1 then Phase 2) suggests they are now comfortable leading focused projects and would likely seek partners who fill specific gaps — clinical trials, manufacturing, or market access — rather than broad research alliances.

NanoVation-GS has built a network of 10 unique partners across 6 countries through 3 projects, reflecting a compact but internationally distributed collaboration base typical of an Israeli SME reaching into the European research ecosystem.

What sets them apart

NanoVation-GS sits at the intersection of nanotechnology and consumer health monitoring — a niche where few SMEs have progressed from EU-funded research all the way to SME Instrument Phase 2 (EUR 2.5M). Their specific combination of nanosensor fabrication expertise and breath analysis know-how is rare and directly applicable to the growing remote patient monitoring market. For consortium builders, they bring both the deep sensor science and the product development drive that turns lab prototypes into devices.

Highlights from their portfolio

• SenseGuard
  Secured EUR 2.5M in SME Instrument Phase 2 funding as coordinator — a highly competitive grant validating commercial readiness of their respiratory monitoring device.
• SNIFFPHONE
  Ambitious multi-partner project combining smartphone technology with breath-based disease detection for gastric cancer screening, where NanoVation-GS contributed core nanosensor expertise.